Article thumbnail
Location of Repository

Protein and cell therapy for lecithin-cholesterol acyltransferase (LCAT) deficiency

By J.K. Low

Abstract

Lecithin-cholesterol acyltransferase (LCAT) is an enzyme principally secreted by the liver into the circulation where it esterifies cholesterol and plays a key role in high- density lipoprotein (HDL) metabolism. In familial and acquired (liver disease) LCAT deficiency, the failure to esterify cholesterol causes many cellular and metabolic disturbances. Here, I describe the purification of recombinant LCAT and assess two approaches to treat LCAT deficiency. Human LCAT cDNA was cloned into a selectable expression vector and used to generate a stably–transfected Chinese hamster ovary (CHO) cells secreting human LCAT tagged with 6 histidine residues. Productive clones were selected, monitoring LCAT activity by a modification of a radioactive enzymic assay for plasma, and the enzyme purified from culture medium by immobilised cobalt affinity chromatography. The pure LCAT, as judged by SDS- PAGE, was used to raise monoclonal antibodies in LCAT knockout mice for future development of a sensitive immunoassay. For therapy, I evaluated injection of pure LCAT into the peritoneal cavity of LCAT knockout mice using single and repeat dose regimes. LCAT activity was measurable in plasma post-injection and the percentage of esterified cholesterol increased, while agarose gel electrophoresis confirmed a rise in HDL levels. In a second approach, I encapsulated the recombinant CHO cells in biocompatible and semipermeable alginate-polylysine microcapsules using a syringe pump extrusion method. A study in vitro showed that, after an initial lag phase, LCAT was secreted for over 90 days with the capsules remaining intact. These microencapsulated cells were implanted into peritoneal cavities of LCAT-deficient mice. LCAT activity was detected in mice plasma one week post-implantation; the relative amount of esterified cholesterol was increased and lipoprotein profile was improved. I conclude that injection of recombinant enzyme or of encapsulated LCAT-secreting cells are feasible therapies for familial and acquired LCAT deficiency

Publisher: UCL (University College London)
Year: 2009
OAI identifier: oai:eprints.ucl.ac.uk.OAI2:14474
Provided by: UCL Discovery

Suggested articles

Citations

  1. (1971). [Mechanism of action of D-galactosamine in the liver].
  2. (2001). [The internal bioartifical liver].
  3. (1983). A DNA insertion in the apolipoprotein A-I gene of patients with premature atherosclerosis.
  4. (1979). A further case of fish-eye disease.
  5. (1969). A lipoprotein characterizing obstructive jaundice.
  6. (1978). A model of fulminant hepatic failure in the rabbit.
  7. (2001). A novel reactor for making uniform capsules.
  8. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.
  9. (1995). A unique genetic and biochemical presentation of fish-eye disease.
  10. (2001). ABCA1. The gatekeeper for eliminating excess tissue cholesterol. J.Lipid Res.
  11. (1985). Activation of lecithin: cholesterol acyltransferase by human apolipoprotein A-IV.
  12. (1993). Acute liver failure: redefining the syndromes.
  13. (2000). Acute liver failure: targeted artificial and hepatocyte-based support of liver regeneration and reversal of multiorgan failure.
  14. (1997). Acute liver failure.
  15. (1985). Adenovirus early region 4 encodes functions required for efficient DNA replication, late gene expression, and host cell shutoff.
  16. (2000). Adenovirus vectors for high-efficiency gene transfer into mammalian cells.
  17. (2001). Adenovirus-mediated gene transfer to liver. Adv.Drug Deliv.Rev.
  18. (1993). Adenovirus-mediated transfer of low density lipoprotein receptor gene acutely accelerates cholesterol clearance in normal mice.
  19. (1990). Alginate as immobilization matrix for cells. Trends Biotechnol.
  20. (2003). Alginate encapsulation of genetically engineered mammalian cells: comparison of production devices, methods and microcapsule characteristics.
  21. (1996). Alginate polycation microcapsules. I. Interaction between alginate and polycation.
  22. (1996). Alginate polycation microcapsules. II. Some functional properties.
  23. (2001). Allo transplants xeno: as bioartificial organs move to the clinic.
  24. (1986). Alterations in isoprenaline sensitivity in patients with cirrhosis: evidence of abnormality of the sympathetic nervous activity.
  25. (1986). Altered renal and platelet arachidonic acid metabolism in cirrhosis.
  26. (1991). An immunologic basis for the fibrotic reaction to implanted microcapsules.
  27. (2001). Analysis of glomerulosclerosis and atherosclerosis in lecithin cholesterol acyltransferase-deficient mice.
  28. (2003). Analysis of polyethylene-glycol-polylactide nano-dimension artificial red blood cells in maintaining systemic hemoglobin levels and prevention of methemoglobin formation.
  29. (1991). Animal models of fulminant hepatic failure.
  30. (2005). Apolipoprotein E delivery by peritoneal implantation of encapsulated recombinant cells improves the hyperlipidaemic profile in apoE-deficient mice.
  31. (1998). Artificial cells with emphasis on cell encapsulation of genetically engineered cells.
  32. (1992). Artificial liver support based on artificial cells with emphasis on encapsulated hepatocytes.
  33. (2002). ATP-binding cassette A1 protein and HDL homeostasis.
  34. (2004). ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins.
  35. (1986). Bioartificial liver: implanted artificial cells microencapsulated living hepatocytes increases survival of liver failure rats.
  36. (1997). Biochemical and biophysical characterization of human recombinant lecithin: cholesterol acyltransferase. J.Lipid Res.
  37. (1984). Biochemistry and clinical relevance of lipoprotein X. Ann.Clin.Lab Sci.
  38. (2006). Biocompatibility of alginate-poly-L-lysine microcapsules for cell therapy.
  39. (1996). Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy.
  40. (1994). Biopharmaceutical R&D success rates and development times. A new analysis provides benchmarks for the future. Biotechnology (N.Y.)
  41. (1992). Biopharmaceuticals and conventional drugs: clinical success rates.
  42. (2000). Biophysical targeting of adenovirus vectors for gene therapy.
  43. (1994). Butyrate synchronization of hepatocytes: modulation of cycling and cell cycle regulated gene expression.
  44. (1998). C-terminal His6-tagged lecithin-cholesterol acyltransferase (LCAT) is catalytically active.
  45. (2006). Cardiac and vascular changes in cirrhosis: pathogenic mechanisms.
  46. (1995). Cell therapy with encapsulated xenogeneic tumor cells secreting beta-endorphin for treatment of peripheral pain.
  47. (1994). Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy.
  48. (1996). Central nervous system delivery of recombinant ciliary neurotrophic factor by polymer encapsulated differentiated C2C12 myoblasts. Hum.Gene Ther.
  49. (1999). Characterization of C-terminal histidine-tagged human recombinant lecithin:cholesterol acyltransferase. J.Lipid Res.
  50. (2004). Characterization of lecithin:cholesterol acyltransferase expressed in a human lung cell line. Protein Expr.Purif.
  51. (1982). Characterization of proteoliposomes containing apoprotein A-I: a new substrate for the measurement of lecithin: cholesterol acyltransferase activity. J.Lipid Res.
  52. (1992). Cholesterol esterifying enzymes - lecithin:cholesterol acyltransferase (LCAT) and acylcoenzyme A:cholesterol acyltransferase (ACAT). Converse and Skinner. Lipoprotein Analysis. A practical approach.
  53. (1995). Cholesteryl ester transfer proteins, reverse cholesterol transport, and atherosclerosis.
  54. (1996). Chromaffin cell survival from both young and old donors is enhanced by co-grafts of polymer-encapsulated human NGF-secreting cells.
  55. (1998). Clonal variability within dihydrofolate reductase-mediated gene amplified Chinese hamster ovary cells: stability in the absence of selective pressure.
  56. (1986). Cloning and expression of human lecithin-cholesterol acyltransferase cDNA.
  57. (2004). Combined immunotherapy and antiangiogenic therapy of cancer with microencapsulated cells. Hum.Gene Ther.
  58. (2005). Comparative study of microcapsules elaborated with three polycations (PLL, PDL, PLO) for cell immobilization.
  59. (1996). Complete deficiency of plasma lecithin-cholesterol acyltransferase (LCAT) activity due to a novel homozygous mutation (Gly-30-Ser) in the LCAT gene.
  60. (1998). Continuous delivery of human and mouse erythropoietin in mice by genetically engineered polymer encapsulated myoblasts. Gene Ther.
  61. (2001). Continuous release of endostatin from microencapsulated engineered cells for tumor therapy.
  62. (1997). Cytomedical therapy for IgG1 plasmacytosis in human interleukin-6 transgenic mice using hybridoma cells microencapsulated in alginate-poly(L)lysine-alginate membrane.
  63. (1973). D-galactosamine and acute liver cell injury.
  64. (1982). Decreased erythrocyte membrane fluidity and altered lipid composition in human liver disease. J.Lipid Res.
  65. (1996). Delivery of human factor IX in mice by encapsulated recombinant myoblasts: a novel approach towards allogeneic gene therapy of hemophilia B.
  66. (1990). Desensitization of myocardial beta-adrenergic receptors in cirrhotic rats.
  67. (1989). Development and evaluation of a system of microencapsulation of primary rat hepatocytes.
  68. (1996). Development of retroviral vectors as safe, targeted gene delivery systems.
  69. (1976). Discoidal bilayer structure of nascent high density lipoproteins from perfused rat liver.
  70. (1997). Disruption of the murine lecithin:cholesterol acyltransferase gene causes impairment of adrenal lipid delivery and upregulation of scavenger receptor class B type I.
  71. (1997). Early region 4 modulates adenovirus DNA replication by two genetically separable mechanisms.
  72. (1993). Effect of hypoxia on insulin secretion by isolated rat and canine islets of Langerhans.
  73. (1994). Effect of microencapsulation on oxygen distribution in islets organs.
  74. (1979). Effect of sodium butyrate on myoblast growth and differentiation.
  75. (1991). Effects of site-directed mutagenesis at residues cysteine-31 and cysteine-184 on lecithin-cholesterol acyltransferase activity.
  76. (1993). Effects of site-directed mutagenesis on the Nglycosylation sites of human lecithin:cholesterol acyltransferase.
  77. (1974). Enzymatic determination of total serum cholesterol.
  78. (1985). Enzymology of lecithin:cholesterol acetyltransferase.
  79. (1985). Evidence for deficiency of high density lipoprotein lecithin: cholesterol acyltransferase activity (alpha-LCAT) in fish eye disease.
  80. (1984). Evidence that renal prostaglandins are involved in renal water metabolism in cirrhosis.
  81. (1999). Expanded-capacity adenoviral vectors--the helper-dependent vectors.
  82. (1968). Experimental hepatitis induced by Dgalactosamine.
  83. (1993). Expression and characterization of recombinant human lecithin:cholesterol acyltransferase. J.Lipid Res.
  84. (1990). Extrahepatic cell membrane lipid abnormalities and cellular dysfunction in liver disease.
  85. (1999). Factors influencing the properties and performance of microcapsules for immunoprotection of pancreatic islets.
  86. (1974). Familial lecithin:cholesterol acyltransferase deficiency--a clinical survey.
  87. (1974). Familial lecithin:cholesterol acyltransferase deficiency. Studies on lipid composition and morphology of tissues.
  88. (1973). Familial plasma lecithin: cholesterol acyltransferase (LCAT) deficiency. Ultrastructural aspects of a new syndrome with particular reference to lesions in the kidneys and the spleen.
  89. (1972). Fatty acid specificity of plasma phosphatidylcholine: cholesterol acyltransferase.
  90. (1982). Fish eye disease: a new familial condition with massive corneal opacities and dyslipoproteinaemia.
  91. (1979). Fish-eye disease. A new familial condition with massive corneal opacities and dyslipoproteinaemia.
  92. (1976). Formation of lipoprotein-X.
  93. (1986). Functions of the adenovirus E1B tumour antigens. Cancer Surv.
  94. (1972). Further aspects on the characterization of high and very low density lipoproteins in patients with liver disease.
  95. (1963). Further studies of the mechanism of the plasma cholesterol esterification reaction.
  96. (1978). Gene amplification and drug resistance in cultured murine cells.
  97. (1991). Gene therapeutics.
  98. (1996). Gene therapy for amyotrophic lateral sclerosis (ALS) using a polymer encapsulated xenogenic cell line engineered to secrete hCNTF. Hum.Gene Ther.
  99. (2004). Gene therapy for hemoglobinopathies: are we there yet?
  100. (1999). Genetic engineering of recombinant glycoproteins and the glycosylation pathway in mammalian host cells.
  101. (1991). Genetically modified skin fibroblasts persist long after transplantation but gradually inactivate introduced genes.
  102. (1975). Genetics of LCAT (lecithin: cholesterol acyltransferase) deficiency.
  103. (1996). Glycosylation structure and enzyme activity of lecithin:cholesterol acyltransferase from human plasma, HepG2 cells, and baculoviral and Chinese hamster ovary cell expression systems. J.Lipid Res.
  104. (1997). Hepatocyte transplantation as a bridge to orthotopic liver transplantation in terminal liver failure.
  105. (2003). Hepatocyte transplantation in the treatment of acute liver failure: microencapsulated hepatocytes versus hepatocytes attached to an autologous biomatrix. Cell Transplant.
  106. (2001). High density lipoprotein (HDL) particle uptake mediated by scavenger receptor class B type 1 results in selective sorting of HDL cholesterol from protein and polarized cholesterol secretion.
  107. (1988). High density lipoprotein particle size distribution in subjects with obstructive jaundice. J.Lipid Res.
  108. (1997). High plasma HDL concentrations associated with enhanced atherosclerosis in transgenic mice overexpressing lecithin-cholesteryl acyltransferase.
  109. (2004). History, challenges and perspectives of cell microencapsulation.
  110. (1976). Holasek A
  111. (1993). Host reaction against alginate-polylysine microcapsules containing living cells.
  112. (1986). Human lecithin-cholesterol acyltransferase gene: complete gene sequence and sites of expression.
  113. (1978). Human plasma lecithin-cholesterol acyltransferase. Characterization of cofactor-dependent phospholipase activity.
  114. (1996). Hyperalphalipoproteinemia in human lecithin cholesterol acyltransferase transgenic rabbits. In vivo apolipoprotein A-I catabolism is delayed in a gene dose-dependent manner.
  115. (1988). Identification of the active-site serine in human lecithin: cholesterol acyltransferase.
  116. (1992). Immobilized metal ion affinity chromatography. Protein Expr.Purif.
  117. (2004). Immunoisolated chromaffin cells implanted into the subarachnoid space of rats reduce cold allodynia in a model of neuropathic pain: a novel application of microencapsulation technology.
  118. (1997). Immunologic barriers to hepatic adenoviral gene therapy for transplantation.
  119. (1996). Immunology of gene therapy with adenoviral vectors in mouse skeletal muscle.
  120. (2002). Improvements in gene therapy: averting the immune response to adenoviral vectors.
  121. (1986). Influence of glucose and oxygen supply conditions on the oxygenation of multicellular spheroids.
  122. (1989). Inhibition of platelet aggregation by abnormal high density lipoprotein particles in plasma from patients with hepatic cirrhosis.
  123. (2004). Inhibition of204 costimulation allows for repeated systemic administration of adenoviral vector in rhesus monkeys. Gene Ther.
  124. (1993). Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment.
  125. (1983). Interspecies activation of lecithin-cholesterol acyltransferase by apolipoprotein A-I isolated from the plasma of humans, horses, sheep, goats and rabbits.
  126. (1969). Intraperitoneal injection of mice.
  127. (1986). Introduction to the plasma lipoproteins. Methods Enzymol.
  128. Its relationship to bile compounds.
  129. (1991). LCAT mRNA in liver disease.
  130. (1991). Lecithin cholesterol acyltransferase deficiency: ultrastructural examination of sequential renal biopsies.
  131. (2000). Lecithin cholesterol acyltransferase.
  132. (1978). Lecithin--cholesterol acyltransferase and the lipoprotein abnormalities of obstructive jaundice.
  133. (1979). Lecithin-cholesterol acyltransferase and the lipoprotein abnormalities of parenchymal liver disease.
  134. (1991). Lecithin-cholesterol acyltransferase in the metabolism of high-density lipoproteins.
  135. (1993). Lecithin-cholesterol acyltransferase: effects of mutagenesis at N-linked oligosaccharide attachment sites on acyl acceptor specificity.
  136. (1987). Lecithin: cholesterol acyltransferase in liver disease. Scand.J.Clin.Lab Invest 47:613-617.202 Foger
  137. (1972). Lecithin: cholesterol acyltransferase: effects of substrate composition upon enzyme activity.
  138. (1981). Lecithin:cholesterol acyltransferase (LCAT) mass; its relationship to LCAT activity and cholesterol esterification rate. J.Lipid Res.
  139. (1993). Lecithin:cholesterol acyltransferase: role of N-linked glycosylation in enzyme function.
  140. (1974). Lipid and lipoprotein abnormalities in liver disease: the possible role of lecithin: cholesterol acyltransferase deficiency.
  141. (1985). Lipoprotein abnormalities in primary biliary cirrhosis. Association with hepatic lipase inhibition as well as altered cholesterol esterification.
  142. (1983). Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis.
  143. (1987). Lipoproteins in liver disease.
  144. (2005). Long-term expression of erythropoietin from myoblasts immobilized in biocompatible and neovascularized microcapsules.
  145. (1990). Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: implications for the pathophysiology of apoB production. J.Lipid Res.
  146. (1980). Low density lipoprotein-activated lysolecithin acylation by human plasma lecithin-cholesterol acyltransferase. Identity of lysolecithin acyltransferase and lecithin-cholesterol acyltransferase.
  147. (1987). Membrane lipid changes in erythrocytes, liver and kidney in acute and chronic experimental liver disease in rats.
  148. (1994). Membrane physical properties determine cardiac beta-adrenergic receptor function in cirrhotic rats. Am.J.Physiol 267:G87-G93.
  149. (1984). Metabolism of apolipoprotein B in large triglyceride-rich very low density lipoproteins of normal and hypertriglyceridemic subjects.
  150. (1991). Metabolism of low-density lipoprotein free cholesterol by human plasma lecithin-cholesterol acyltransferase.
  151. (1975). Metal chelate affinity chromatography, a new approach to protein fractionation.
  152. Method for quantitative separation and identification of lipoproteins in jaundiced subjects.
  153. (1997). Microcapsules as bio-organs for somatic gene therapy.
  154. (1994). microcapsules: II--Parameters governing the production of alginate beads by high voltage electrostatic pulses. Cell Transplant.
  155. (2001). Microencapsulated cell-mediated treatment of inoperable pancreatic carcinoma.
  156. (1986). Microencapsulated hepatocytes as a bioartificial liver.
  157. (2002). Microencapsulated iNOS-expressing cells cause tumor suppression in mice.
  158. (1980). Microencapsulated islets as bioartificial endocrine pancreas.
  159. (1996). Microencapsulation and transplantation of genetically engineered cells: a new approach to somatic gene therapy. Artif.Cells Blood Substit.Immobil.Biotechnol.
  160. (2001). Microencapsulation of human parathyroid cells: an "in vitro" study.
  161. (1996). Molecular analysis of T lymphocyte-directed gene therapy for adenosine deaminase deficiency: long-term expression in vivo of genes introduced with a retroviral vector. Hum.Gene Ther.
  162. (1976). Morphological and biochemical differentiation in HeLa cells. Effects of cycloheximide on butyrate-induced process formation and ganglioside metabolism. Exp.Cell Res.
  163. (1973). Morphology and growth rate changes in Chinese hamster cells cultured in presence of sodium butyrate. Exp.Cell Res.
  164. (1992). Mouse apolipoprotein AI. cDNA-derived primary structure, gene organisation and complete nucleotide sequence.
  165. (1977). n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells.
  166. (1987). New metal chelate adsorbent selective for proteins and peptides containing neighbouring histidine residues.
  167. (1996). Normalization of diabetes in spontaneously diabetic cynomologus monkeys by xenografts of microencapsulated porcine islets without immunosuppression.
  168. (1979). Ocular manifestations of familial high-density lipoprotein deficiency (Tangier disease).
  169. (1993). One-step purification of recombinant human papillomavirus type 16 E7 oncoprotein and its binding to the retinoblastoma gene product.
  170. (1971). Origin and disappearance of plasma lecithin: cholesterol acyltransferase.
  171. (1995). Overexpression of human lecithin cholesterol acyltransferase leads to hyperalphalipoproteinemia in transgenic mice.
  172. (1996). Overexpression of lecithin:cholesterol acyltransferase in transgenic rabbits prevents dietinduced atherosclerosis.
  173. (1985). Paradoxical esterification of plasma cholesterol in fish eye disease.
  174. (1985). Pathogenesis and management of lipoprotein disorders.
  175. (1999). Physico-chemical and mass transfer considerations in microencapsulation.
  176. (1990). Plasma high density lipoproteins. Metabolism and relationship to atherogenesis.
  177. (1990). Plasma lecithin/cholesterol acyltransferase (LCAT) activity in multiple-organ donors: a predictor of allograft viability in clinical liver transplantation.
  178. (1983). Plasma lipids, lipoproteins and cell membranes.
  179. (1971). Plasma lipoproteins in familial lecithin: cholesterol acyltransferase deficiency: physical and chemical studies of low and high density lipoproteins.
  180. (1981). Platelet lipid composition and platelet aggregation in human liver disease. J.Lipid Res.
  181. (2001). Poly-LLysine induces fibrosis on alginate microcapsules via the induction of cytokines.
  182. (1993). Polydisperse dextran as a diffusing test solute to study the membrane permeability of alginate polylysine microcapsules. Biomater.Artif.Cells Immobilization Biotechnol.
  183. (1995). Polymer encapsulated cell lines genetically engineered to release ciliary neurotrophic factor can slow down progressive motor neuronopathy in the mouse.
  184. (1994). Polymer-encapsulated cells genetically modified to secrete human nerve growth factor promote the survival of axotomized septal cholinergic neurons.
  185. (1982). Population-based reference values for lecithin-cholesterol acyltransferase (LCAT).
  186. (1998). Portal branch ligation with a continuous hepatocyte growth factor supply makes extensive hepatectomy possible in cirrhotic rats.
  187. (1974). Possible association between an abnormal low density lipoprotein and nephropathy in lecithin: cholesterol acyltransferase deficiency.
  188. (1996). Potential gene therapy for lecithin-cholesterol acyltransferase (LCAT)-deficient and hypoalphalipoproteinemic patients with adenovirus-mediated transfer of human LCAT gene.
  189. (1990). Prevention of CTL and NK cell-mediated cytotoxicity by microencapsulation.
  190. (1973). Prevention of galactosamine-induced liver cell necrosis by uridine.
  191. (1991). Primary biliary cirrhosis: paradigm or paradox for autoimmunity.
  192. (1995). Primary sclerosing cholangitis.
  193. (1984). Progress in understanding the LDL receptor and HMG-CoA reductase, two membrane proteins that regulate the plasma cholesterol. J.Lipid Res.
  194. (1984). Prostaglandin synthesis linked to phosphatidylinositol turnover in isolated rat glomeruli.
  195. (1971). Purification and substrate specificity of lecithin-cholesterol acyl transferase from human plasma.
  196. (1987). Recent studies on the mechanism of induction of differentiation in murine erythroleukemia cells. Haematologica 72:75.
  197. (1973). Recircularization and autonomous replication of a sheared R-factor DNA segment in Escherichia coli transformants.
  198. (1993). Recognition of complex carbohydrates by the macrophage mannose receptor.
  199. (1971). Ref Type: Generic Gjone E, Blomhoff JP, and Wiencke I
  200. (1978). Refinement of the coomassie blue method of protein quantitation. A simple and linear spectrophotometric assay for less than or equal to 0.5 to 50 microgram of protein.
  201. (1998). Regulation of lecithin cholesterol acyltransferase activity. Prog.Lipid Res.
  202. (1982). Renal failure in familial lecithin: cholesterol acyltransferase deficiency.
  203. (1986). Renal lesions in familial lecithin-cholesterol acyltransferase deficiency. Ultrastructural heterogeneity of glomerular changes.
  204. (2005). Review article: current management of primary sclerosing cholangitis.
  205. (1985). Role of the liver in the degradation of lipoproteins.
  206. (1993). Roles of cysteines in human lecithin:cholesterol acyltransferase.
  207. (2001). Scavenger receptor class B type I is a multiligand HDL receptor that influences diverse physiologic systems.
  208. (1991). Secretion in yeast. Purification and in vitro translocation of chemical amounts of prepro-alpha-factor.
  209. (1995). Secretion of active human lecithin-cholesterol acyltransferase by insect cells infected with a recombinant baculovirus.
  210. (1976). Secretion of lecithin: cholesterol acyltransferase from isolated rat hepatocytes.
  211. (1982). Secretion of nascent lipoproteins and apolipoproteins by perfused livers of normal and cholesterol-fed guinea pigs. J.Lipid Res.
  212. (1964). Semipermeable microcapsules.
  213. (1989). Significance of lecithin:cholesterol acyltransferase activity as a prognostic indicator of early allograft function in clinical liver transplantation.
  214. (1964). Some properties of a cholesterol esterifying enzyme in human plasma.
  215. (1979). Stability and properties of lecithin-cholesterol acyltransferase.
  216. (1994). Stable delivery of physiologic levels of recombinant erythropoietin to the systemic circulation by intramuscular injection of replicationdefective adenovirus.
  217. (1999). Studies on small (<350 microm) alginate-poly-L-lysine microcapsules. III. Biocompatibility Of smaller versus standard microcapsules.
  218. (1999). Surface plasmon resonance biosensor studies of human wild-type and mutant lecithin cholesterol acyltransferase interactions with lipoproteins.
  219. (2003). Survival of different cell lines in alginate-agarose microcapsules.
  220. (2000). Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver.
  221. (2002). Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy.
  222. (1983). Sympathetic nervous activity, renin-angiotensin system and renal excretion of prostaglandin E2 in cirrhosis. Relationship to functional renal failure and sodium and water excretion.
  223. (1986). Synthesis and secretion of lecithincholesterol acyltransferase by the human hepatoma cell line HepG2. Biochim.Biophys.Acta 877:433-439.200
  224. (1997). Targeted disruption of the mouse lecithin:cholesterol acyltransferase (LCAT) gene. Generation of a new animal model for human LCAT deficiency.
  225. (2000). Technology of mammalian cell encapsulation. Adv.Drug Deliv.Rev.
  226. (1994). The capsular overgrowth on microencapsulated pancreatic islet grafts in streptozotocin and autoimmune diabetic rats.
  227. (2000). The development and first clinical use of semipermeable microcapsules (artificial cells) as a compact artificial kidney.
  228. (1991). The effect of capsule composition on the biocompatibility of alginate-poly-l-lysine capsules.
  229. (1992). The effect of sodium butyrate on the growth characteristics of human cervix tumour cells.
  230. (1988). The genetics of haemochromatosis.
  231. (1985). The LDL receptor and the regulation of cellular cholesterol metabolism.
  232. (1962). The mechanism of the plasma cholesterol esterification reaction: plasma fatty acid transferase.
  233. (2006). The medical management of primary sclerosing cholangitis. Semin.Liver Dis.
  234. (1997). The molecular pathology of lecithin:cholesterol acyltransferase (LCAT) deficiency syndromes. J.Lipid Res.
  235. (1990). The role of CD4+ helper T cells in the destruction of microencapsulated islet xenografts in nod mice.
  236. (1987). The role of LCAT and cholesteryl ester transfer proteins for the HDL and LDL structure and metabolism.
  237. (1992). The role of oxygen supply in islet transplantation.
  238. (1988). The viability and regeneration of artificial cell microencapsulated rat hepatocyte xenograft transplants in mice.
  239. (1989). Tissue-specific expression, developmental regulation, and chromosomal mapping of the lecithin: cholesterol acyltransferase gene. Evidence for expression in brain and testes as well as liver.
  240. (1995). Transplantation of allogeneic hepatocytes without immunosuppression: long-term survival.
  241. (1997). Transplantation of encapsulated cells and tissues.
  242. (1996). Transport characterization of membranes for immunoisolation.
  243. (1999). Treatment of type I diabetes using encapsulated islets. Adv.Drug Deliv.Rev.
  244. (1996). Two novel molecular defects in the LCAT gene are associated with fish eye disease.
  245. (2008). would like to thank my mother, sisters and brothers especially Jee Ming who constantly ask “Have you finished writing your thesis yet?” Jee Low,
  246. (1998). Xenotransplantation of cells and tissues: application to a range of diseases, from diabetes to Alzheimer's.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.